Literature DB >> 16462537

Optimizing quality of outpatient care for patients with inflammatory bowel disease: the importance of specialist clinics.

Joel E D Mawdsley1, Peter M Irving, Richard J Makins, David S Rampton.   

Abstract

BACKGROUND: Most patients with inflammatory bowel disease (IBD) undergo long-term outpatient follow up. However, quality of care provided by specialist and non-specialist IBD clinics is rarely critically audited.
OBJECTIVE: To compare the standard of outpatient care provided by general gastroenterology and specialist IBD clinics within a single hospital using defined quality criteria.
METHODS: The case notes of 60 consecutive patients with IBD attending general gastroenterology clinics and of 100 patients attending the specialist IBD clinic were reviewed for fulfillment of six quality criteria over the preceding 18 months.
RESULTS: The proportion of patients fulfilling all six criteria was higher in the specialist IBD clinic. In the specialist IBD clinic, compared with the general gastroenterology clinics, blood tests were performed with appropriate frequency during the initiation of immunosuppressive treatment in 7/11 versus 2/12 patients (P=0.04) and during maintenance in 24/31 versus 6/21 patients (P=0.001); bone protection with oral steroids were given to 25/53 versus 4/24 patients (P=0.01); a screening colonoscopy at 8-10 years was performed in 25/27 versus 11/20 patients with ulcerative colitis (P=0.004); annual serum urea and creatinine concentrations were measured in 82/89 versus 31/45 patients prescribed 5-aminosalicylates (P=0.001); annual liver function tests were performed in 96/100 versus 38/60 patients (P=0.001); and annual haematinics were measured in 37/47 versus 18/33 patients with Crohn's disease (P=0.03).
CONCLUSION: By these criteria, the specialist IBD clinic provided better care than the non-specialist general gastroenterology clinics. Even in the specialist clinic, however, the care of a minority of patients did not fulfil certain criteria, emphasizing the need for a critical audit of outpatient management of IBD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16462537     DOI: 10.1097/00042737-200603000-00004

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  14 in total

1.  Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease.

Authors:  Javier P Gisbert; María Chaparro; Fernando Gomollón
Journal:  World J Gastroenterol       Date:  2011-08-14       Impact factor: 5.742

Review 2.  Quality of health care in the United States: implications for pediatric inflammatory bowel disease.

Authors:  Brendan M Boyle; Lena Palmer; Michael D Kappelman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2009-09       Impact factor: 2.839

Review 3.  Timing of surgery in Crohn's disease: a key issue in the management.

Authors:  Rafael Alós; Joaquín Hinojosa
Journal:  World J Gastroenterol       Date:  2008-09-28       Impact factor: 5.742

4.  Racial disparities in utilization of specialist care and medications in inflammatory bowel disease.

Authors:  Geoffrey C Nguyen; Thomas A LaVeist; Mary L Harris; Ming-Hsi Wang; Lisa W Datta; Steven R Brant
Journal:  Am J Gastroenterol       Date:  2010-05-18       Impact factor: 10.864

5.  Impact of Specialized Inpatient IBD Care on Outcomes of IBD Hospitalizations: A Cohort Study.

Authors:  Cindy C Y Law; Saranya Sasidharan; Rodrigo Rodrigues; Deanna D Nguyen; Jenny Sauk; John Garber; Cosmas Giallourakis; Ramnik Xavier; Hamed Khalili; Vijay Yajnik; Ashwin N Ananthakrishnan
Journal:  Inflamm Bowel Dis       Date:  2016-09       Impact factor: 5.325

6.  A dedicated inflammatory bowel disease service quantitatively and qualitatively improves outcomes in less than 18 months: a prospective cohort study in a large metropolitan centre.

Authors:  Vinh-An Huu Phan; Daniel R van Langenberg; Rachel Grafton; Jane M Andrews
Journal:  Frontline Gastroenterol       Date:  2012-05-01

7.  Healthcare Providers Underestimate Patients' Glucocorticoid Use in Crohn's Disease.

Authors:  Subrata Ghosh; Brian Bressler; Jill Petkau; Roopal B Thakkar; Song Wang; Martha Skup; Jingdong Chao; Remo Panaccione; Stefan Schreiber
Journal:  Dig Dis Sci       Date:  2019-01-19       Impact factor: 3.199

8.  Guideline recommendations for treatment of patients with inflammatory bowel diseases are not implemented in clinical practice-results of a non-representative survey.

Authors:  Lea I Kredel; Oliver Schneidereit; Jörg C Hoffmann; Britta Siegmund; Jan C Preiß
Journal:  Int J Colorectal Dis       Date:  2018-12-07       Impact factor: 2.571

Review 9.  Emerging treatment options for extraintestinal manifestations in IBD.

Authors:  Thomas Greuter; Florian Rieder; Torsten Kucharzik; Laurent Peyrin-Biroulet; Alain M Schoepfer; David T Rubin; Stephan R Vavricka
Journal:  Gut       Date:  2020-08-26       Impact factor: 31.793

Review 10.  Web-based interventions for ulcerative colitis and Crohn's disease: systematic review and future directions.

Authors:  Colleen Stiles-Shields; Laurie Keefer
Journal:  Clin Exp Gastroenterol       Date:  2015-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.